CSPC Megalith Biopharmaceutical
Privately held: no public share price
Assets
(1 total)
1Total Assets
0Approved
1Phase 3 / Filed
0Phase 1–2 / Early
2Diseases
Quick filter:
| Target & Modality | |||
|---|---|---|---|
| Phase 3 | Nectin-4Antibody–drug conjugate | Cervical CancerBladder / Urothelial Cancer Urothelial Carcinoma |
Upcoming events
(6 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2027 (3)
2028 (2)
2029 (1)
June 2029 (1)
Est. primary completion 2029-06-01 · NCT07526792 · CT.gov ↗
What to watch
Financial reports
No financial reports recorded.